Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is identified as a product containing cabozantinib, a targeted anticancer medicine used in selected oncology treatment settings. The stated strengths for this product are 20 mg and 80 mg. Cabozantinib belongs to the multi-target receptor tyrosine kinase inhibitor class and acts on several molecular pathways associated with cancer-cell growth, tumor angiogenesis, cellular survival and metastatic progression.

Understanding Caboxen requires distinguishing three separate aspects of medicine information: the generic active ingredient, the commercial brand and the specific pharmaceutical formulation. Although these terms are related, they are not interchangeable.

Cabozantinib is the generic medicine name. Caboxen is the brand name identified by this website. The stated strengths are 20 mg and 80 mg. However, the specific Caboxen manufacturer, dosage form and regulatory status require confirmation through original product documentation.

What Is Caboxen?

Caboxen is presented on this website as a cabozantinib-containing product available in 20 mg and 80 mg strengths.

Cabozantinib is a small-molecule anticancer medicine that inhibits several receptor tyrosine kinases. These receptors regulate important cellular processes, including proliferation, survival, migration, angiogenesis and communication between tumor cells and their surrounding environment.

The medicine is used in selected cancers under specific prescribing conditions.

Cabozantinib is not a general-purpose cancer treatment. It is prescribed according to the cancer type, disease stage, previous treatment, formulation and applicable regulatory indication.

Generic Name: Cabozantinib

The generic name of the medicine identified for Caboxen is cabozantinib.

Cabozantinib was developed as a targeted kinase inhibitor. Its pharmacological activity includes inhibition of MET, VEGFR-1, VEGFR-2, VEGFR-3 and AXL, alongside other receptor tyrosine kinases.

These targets are important because cancer cells and tumor-associated tissues can use their signaling pathways to support disease progression.

Cabozantinib’s activity against multiple targets distinguishes it from medicines designed to inhibit only one receptor or one molecular pathway.

Therapeutic Classification

Cabozantinib belongs to the following medicine categories:

ClassificationDescription
Generic medicineCabozantinib
Therapeutic categoryAntineoplastic agent
Pharmacological classMulti-target tyrosine kinase inhibitor
Main biological activityReceptor tyrosine kinase inhibition
Main molecular targetsMET, VEGFR and AXL, among others
Administration routeOral for established capsule and tablet formulations
Medical specialtyOncology

Its classification as a targeted anticancer medicine reflects its action on specific signaling proteins involved in tumor development.

How Cabozantinib Works

Cabozantinib inhibits several receptor tyrosine kinases that participate in tumor growth and angiogenesis.

MET inhibition

MET is a receptor associated with the hepatocyte growth factor signaling pathway. It can influence cell proliferation, survival, migration and invasion.

Abnormal MET activity may contribute to cancer progression and metastatic behavior.

Cabozantinib’s inhibition of MET can interfere with these signaling processes.

VEGFR inhibition

VEGFR receptors participate in angiogenesis, the process through which new blood vessels form.

Growing tumors may depend on the development of new blood vessels to receive oxygen and nutrients.

Cabozantinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3, thereby interfering with signaling involved in tumor-associated blood-vessel formation.

AXL inhibition

AXL is a receptor tyrosine kinase involved in cell survival, migration and tumor progression.

AXL signaling may also contribute to treatment resistance and changes in tumor-cell behavior.

Cabozantinib’s activity against AXL contributes to its multi-target pharmacological profile.

Other molecular targets

Cabozantinib also inhibits additional kinases, including RET, KIT, ROS1, TYRO3, MER, TRKB, FLT-3 and TIE-2.

The combined activity of these targets helps explain its use in selected

Medical Conditions Associated With Cabozantinib

The established tablet formulation has recognized indications in several oncology settings.

Advanced Renal Cell Carcinoma

Renal cell carcinoma is a malignant disease originating in kidney tissue.

Cabozantinib tablets can be used as monotherapy in specified advanced RCC settings. They can also be prescribed in combination with nivolumab as first-line treatment for eligible adults with advanced renal cell carcinoma.

Hepatocellular Carcinoma

Hepatocellular carcinoma is a primary cancer arising from liver cells.

Cabozantinib tablets are used in specified patients who have previously received sorafenib.

Differentiated Thyroid Cancer

Differentiated thyroid cancer develops from thyroid follicular cells.

For certain patients with locally advanced or metastatic disease that has progressed after previous VEGFR-targeted treatment and is resistant to or unsuitable for radioactive iodine, cabozantinib tablets may be an option.

Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors originate in hormone-producing cells within the pancreas.

Cabozantinib tablets received U.S. approval for specified previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors.

Extra-Pancreatic Neuroendocrine Tumors

Extra-pancreatic neuroendocrine tumors develop outside the pancreas. Their location and biological behavior vary.

Cabozantinib tablets are approved in specified previously treated, unresectable, locally advanced or metastatic, well-differentiated cases.

The exact patient eligibility requirements must be checked against the relevant prescribing documentation.

Important Difference Between Cabozantinib Formulations

One of the most important considerations when reviewing Caboxen is the distinction between cabozantinib tablets and capsules.

The FDA identifies two separate reference products:

Reference productFormulationLabeled strengths
CABOMETYXTablets20 mg, 40 mg, 60 mg
COMETRIQCapsules20 mg, 80 mg

The capsule formulation is associated with the COMETRIQ prescribing information for progressive metastatic medullary thyroid cancer. The tablet formulation has a broader set of approved indications, including specified kidney, liver, thyroid and neuroendocrine cancers.

The two formulations are not bioequivalent and should not be substituted for one another.

Therefore, although Caboxen is listed in 20 mg and 80 mg strengths, these figures alone cannot confirm the formulation or its approved uses.

General Administration Information

Cabozantinib is taken orally according to the instructions for the specific formulation.

For the reference COMETRIQ capsule formulation, the U.S. prescribing information specifies taking the medicine on an empty stomach, avoiding food for at least two hours before and at least one hour after administration.

For CABOMETYX tablets, the U.S. instructions are at least one hour before or at least two hours after eating.

The patient should swallow the prescribed dosage form according to its official instructions. Tablet and capsule handling instructions must not be transferred between formulations.

Missed doses, dose modifications and treatment interruptions should be managed according to the applicable product label and the treating specialist’s instructions.

Important Safety Considerations

Cabozantinib can produce significant adverse reactions.

Patients should be monitored for:

  • Hypertension.
  • Diarrhea.
  • Hemorrhage.
  • Thromboembolic events.
  • Gastrointestinal perforation.
  • Fistula formation.
  • Proteinuria.
  • Liver abnormalities.
  • Hand-foot skin reactions.
  • Impaired wound healing.
  • Osteonecrosis of the jaw.
  • Cardiac failure.
  • Neurological complications.
  • Hypocalcemia.

Surgery and dental procedures require particular attention because cabozantinib can interfere with wound healing.

Pregnancy must also be discussed before treatment because cabozantinib can cause fetal harm.

Caboxen Brand and Manufacturer Information

The product information currently established for this website is:

AttributeInformation
BrandCaboxen
Generic medicineCabozantinib
Stated strengths20 mg and 80 mg
Therapeutic classMulti-target tyrosine kinase inhibitor
RouteTo be confirmed from product documentation
Dosage formTo be confirmed
Specific manufacturerNot independently verified
Regulatory statusNot independently verified

CABOMETYX and COMETRIQ are reference products, not alternative names for Caboxen.

The manufacturer of Caboxen should be identified from its actual packaging, official product leaflet or applicable regulatory record.

Who Should Use Caboxen?

Cabozantinib treatment is intended for patients who meet the clinical requirements for a recognized treatment indication.

Before considering treatment, the oncology team evaluates:

  • The confirmed cancer diagnosis.
  • Cancer stage and disease progression.
  • Previous anticancer treatment.
  • Liver and kidney function.
  • Blood pressure.
  • Cardiovascular history.
  • Bleeding risks.
  • Current medicines.
  • Pregnancy and breastfeeding considerations.
  • The suitability of the specific formulation.

A patient should not choose Caboxen based only on the strength printed on a product listing.

Why Product Verification Matters

Product verification helps establish whether a medicine is correctly identified and supplied through an appropriate pharmaceutical channel.

For Caboxen, the product package should be checked for its generic ingredient, dosage form, strength, manufacturer, batch number, manufacturing date, expiry date and relevant authorization information.

A brand name or packaging design alone does not establish authenticity.

Medical Disclaimer

This page provides general educational information about Caboxen and cabozantinib. It is not a substitute for official prescribing information, medical assessment or individualized treatment advice.

Cabozantinib is a prescription anticancer medicine. The correct formulation, indication, dosage and monitoring plan must be determined by a qualified healthcare professional.

Patients should never change or discontinue treatment independently.